ANTITHROMBOTIC THERAPY AND CARDIOVASCULAR RISK IN PATIENTS WITH ATRIAL FIBRILLATION AT HIGH RISK FOR THROMBOEMBOLIC EVENTS AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: FROM THE PARTNER 2 TRIAL

We sought to determine patterns of antithrombotic therapy use and impact on clinical outcomes in patients with AF and CH2ADS2-VASc2 score ≥ 2 undergoing transcatheter aortic valve replacement (TAVR). In the randomized PARTNER 2 trial and associated registries, 1662 patients with history of AF and